Phase 1b Double-blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Pain Due to Moderate to Severe Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 24 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Nov 2020.
- 24 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Nov 2019.
- 19 Jun 2019 According to an Sorrento Therapeutics media release, this study has generated positive data and met the day 84 goals set for the resiniferatoxin (RTX) program to advance the investigational drug product into Phase 3 clinical trials.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History